- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT01746264
Effect of Vitamin D Supplementation on Endothelial Function in Obese Adolescents
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
Subjects had a brief screening visit with one of the study team members. Past medical history, current medications and a brief dietary history was taken. The dietary history was taken to assess calcium intake in a day and was obtained via the validated Short Calcium questionnaire. Blood pressure, heart rate as well as height,weight, waist and hip circumference measurement was obtained by study staff. In addition, a brief physical examination to determine Tanner stage was also completed. This involved examination of both breasts and genitalia for adolescent female and only genitalia in males. A physical activity questionnaire (IPAQ) was also administered by the study staff at this visit. A blood draw of 5 ml to measure plasma 25(OH) D, calcium, phosphorus was obtained as part of the screening visit. For girls who had started menstruating, a urine pregnancy test was also obtained.
After the screening visit eligible subjects had baseline biochemical tests and an endothelial function assessment. Study participants received a pill container with six total pills of vitamin cholecalciferol (D3) (1 pill = 50,000 IU), with directions to take two pills once a month (100,000 IU) at the same time for a period of 3 months. Compliance was assessed at the 3 month visit by counting the number of pills remaining in the container.
At 1 month, the subjects had tests for serum calcium and 25 hydroxy vitamin D levels. A urine test for random calcium to creatinine ratio was also obtained.
At 2 months, the serum calcium, 25 hydroxy vitamin D levels, and calcium to creatinine ratio tests were repeated.
At the end of 3 months, biochemical tests and an endothelial function assessment were repeated. Medical history, questionnaires, and the physical exam were also repeated.
Tipo de estudio
Inscripción (Actual)
Fase
- Fase 1
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Minnesota
-
Rochester, Minnesota, Estados Unidos, 55905
- Mayo Clinic
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Age 12-18 years
- BMI >95% for age and gender
- 25 (OH) D levels less than 30 ng/ml
Exclusion Criteria:
- 25 (OH) D levels >30 ng/mL
- Serum calcium >10.4 mg/dL
- Serum phosphorus > 4.7 mg/dl
- Pregnancy or nursing
- Current cancer
- Patients on vitamin D3 supplementation exceeding 400 IU/day
- Hypertension defined as Blood Pressure over the 95th percentile for age, gender and height
- Dietary calcium intake exceeding 1500 mg/day
- Hepatic or renal disorders
- Type 1 or type 2 diabetes mellitus
- Subjects receiving insulin, metformin, or oral hypoglycemic medications
- Subjects with malabsorption disorders (celiac disease, cystic fibrosis, inflammatory bowel disease)
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Prevención
- Asignación: N / A
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
---|---|
Experimental: Vitamin D3
Vitamin D3 supplementation at 100,000 IU once a month for 3 months
|
Vitamin D 3 at 100,000 IU once a month for 3 months
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Flow Mediated Dilatation (FMD)
Periodo de tiempo: baseline, 3 months
|
Endothelial function was assessed by FMD, via a high-resolution Doppler ultrasonography examination of the right brachial artery.
FMD was calculated as the maximal percentage increase in brachial artery diameter (BAD) from baseline after the release of cuff occlusion.
|
baseline, 3 months
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
25-hydroxy Vitamin D (25[OH]D) Levels
Periodo de tiempo: baseline, 3 months
|
25(OH)D was measured using liquid chromatography-tandem mass spectrometry.
Total 25(OH)D concentrations of each sample was calculated using internal standard, 25(OH)D_2 and 25(OH)D_3.
|
baseline, 3 months
|
Total Cholesterol
Periodo de tiempo: baseline, 3 months
|
Total cholesterol levels were measured by an enzymatic colorimetric assay.
|
baseline, 3 months
|
Triglycerides
Periodo de tiempo: baseline, 3 months
|
Total triglyceride levels were measured by an enzymatic colorimetric assay.
|
baseline, 3 months
|
Body Mass Index
Periodo de tiempo: baseline, 3 months
|
Body Mass Index (BMI) is a health index for comparing weight to height.
BMI is a person's weight in kilograms (kg) divided by his or her height in meters squared.
The body mass index is an indication if a person is at a suitable weight for his height on an approximation of body fat.
A body mass index of under 20 is considered to be underweight, while a body mass index between 20 to 25 is considered healthy.
A body mass index in the range of 25 to 30 is regarded as overweight.
A body mass index over 30 is regarded as obese.
|
baseline, 3 months
|
International Physical Activity Questionnaire (IPAQ) Short Form Score
Periodo de tiempo: baseline, 3 months
|
The IPAQ short form used asked 7 questions about activities in the last 7 days, covering vigorous physical activities, moderate activities, walking, and sitting, asking for days per week, hours per day or minutes per day.
The score is reported in metabolic equivalent (MET)-minutes per week.
Possible scores could range from 0 (inactive) to greater than 3000 MET-minutes/week (highly active).
The definition of high activity was vigorous intensity activity on at least 3 days achieving a minimum total activity of at least 1500 MET-minutes/week OR 7 days of any combination of walking, moderate-intensity or vigorous-intensity activities achieving a minimum total physical activity of at least 3000 MET-minutes/week.
Therefore a score of > 3000 MET-minutes/week was possible.
|
baseline, 3 months
|
Calcium Intake Per Day
Periodo de tiempo: baseline, 3 months
|
Calcium intake was measured using the validated Short Calcium Questionnaire (SCQ).
This questionnaire is in the form of an spreadsheet, and asks the participant to enter the number of servings per week of various food items and vitamin or mineral supplements.
The spreadsheet calculates the daily calcium intake (mg/day) from the data entered.
|
baseline, 3 months
|
Serum Parathyroid Hormone (PTH)
Periodo de tiempo: baseline, 3 months
|
A parathyroid hormone (PTH) blood test measures the level of parathyroid hormone in the blood.
This test is used to help identify hyperparathyroidism, to find the cause of abnormal calcium levels, or to check the status of chronic kidney disease.
PTH controls calcium and phosphorus levels in the blood.
PTH was measured by a two-site chemiluminescent immunometric assay.
|
baseline, 3 months
|
Fasting Glucose
Periodo de tiempo: baseline, 3 months
|
Plasma glucose was measured by hexokinase enzymatic assay.
|
baseline, 3 months
|
Fasting Insulin
Periodo de tiempo: baseline, 3 months
|
Serum insulin was measured using commercial electrochemiluminescence immunoassay kits.
|
baseline, 3 months
|
Homeostatic Model Assessment of Insulin Resistance Index (HOMA-IR)
Periodo de tiempo: baseline, 3 months
|
This calculation measures insulin resistance, and requires U.S. standard units.
The healthy range is 0.5 to 1.4.
Less than 1.0 means the subject is insulin-sensitive, which is optimal.
Above 1.9 indicates early insulin resistance.
Above 2.9 indicates significant insulin resistance.
The HOMA-IR was calculated as: HOMA-IR = fasting serum glucose (mmol/L) x fasting insulin (mU/mL)/22.5.
|
baseline, 3 months
|
High Sensitivity C-reactive Protein (Hs-CRP)
Periodo de tiempo: baseline, 3 months
|
A high-sensitivity C-reactive protein (hs-CRP) test may be used to help evaluate an individual for risk of cardiovascular disease (CVD).
C-reactive protein (CRP) is a protein that increases in the blood with inflammation.
Studies have suggested that a persistent low level of inflammation plays a major role in atherosclerosis, the narrowing of blood vessels due to build-up of cholesterol and other lipids, which is often associated with CVD.
The hs-CRP test accurately measures low levels of C-reactive protein to identify low but persistent levels of inflammation and thus helps predict a person's risk of developing CVD.
hs-CRP was measured using particle-enhanced immunonephelometry.
|
baseline, 3 months
|
Low-density Lipoprotein Cholesterol (LDL) Cholesterol Levels
Periodo de tiempo: baseline, 3 months
|
The test for low-density lipoprotein cholesterol is used as part of a lipid profile to predict an individual's risk of developing heart disease.
A desirable level is <3.36 mmol/L; borderline high is 3.36 - 4.11 mmol/L; high is >/= 4.14 mmol/L.
LDL cholesterol was calculated as: LDL = Total cholesterol - HDL cholesterol - Triglycerides/5.
|
baseline, 3 months
|
High Density Lipoprotein (HDL) Cholesterol Levels
Periodo de tiempo: baseline, 3 months
|
Total HDL cholesterol levels were measured by an enzymatic colorimetric assay.
The test for high-density lipoprotein cholesterol (HDL-C) is used along with other lipid tests to screen for unhealthy levels of lipids and to determine the risk of developing heart disease.
If a subject has a negative risk factor, a desirable HDL level would be >/= 1.55 mmol/L.
|
baseline, 3 months
|
Urine Calcium to Creatinine Ratio
Periodo de tiempo: baseline, 3 months
|
Urine calcium/creatinine ratio (unit mg/g) on random urine sample was calculated by dividing calcium in mg by creatinine in g.
|
baseline, 3 months
|
Reactive Hyperemia Index (RHI)
Periodo de tiempo: baseline, 3 months
|
The cuff of a sphygmomanometer was placed on the forearm and inflated to 50 mm Hg above the participant's systolic blood pressure for a period of 5 min.
The increase in resting brachial blood flow was calculated as the maximum flow recorded in the first 15 seconds after cuff deflation and expressed as a percentage increase from baseline reactive.
Higher values are considered normal or improved endothelial function.
|
baseline, 3 months
|
Colaboradores e Investigadores
Patrocinador
Publicaciones y enlaces útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Estimar)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- 12-006349
- UL1TR000135 (Subvención/contrato del NIH de EE. UU.)
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Vitamin D3
-
Aalborg UniversityAalborg University Hospital; CCBR Aalborg A/S, Aalborg, DenmarkTerminadoMigraña según los criterios de la International Headache Society (IHS) (ICHD-II)Dinamarca
-
Tata Memorial CentreReclutamiento
-
University of California, San FranciscoTerminado
-
Moscow Clinical Scientific CenterReclutamientoNeoplasias Cecales | Neoplasias colónicas malignasFederación Rusa
-
Aga Khan UniversityTerminadoDeficiencia de vitamina DPakistán
-
Cedars-Sinai Medical CenterTerminadoDeficiencia de vitamina D | Enfermedad de CrohnEstados Unidos
-
Medical University of South CarolinaThrasher Research FundTerminadoDeficiencia de vitamina D | El embarazoEstados Unidos
-
University of NottinghamAbbeyfieldTerminadoSarcopenia | Atrofia muscularReino Unido
-
DSM Nutritional Products, Inc.Leatherhead Food ResearchTerminadoOsteoporosis